
Record revenue and EBITDA in 2025, with net income up 45% year-over-year. Growth driven by higher intake and ticket prices, especially in core and medical segments, while maintaining strong cash generation and disciplined leverage. Confident outlook for 2026.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.